Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab + chemotherapy ± anlotinib in advanced nasopharyngeal carcinoma (Phase II)
ChiCTR2500104805Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of penpulimab in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate (ORR). Started Sep 2020; status: completed.
02
Drugs
penpulimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500104805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104805.